Altamira Therapeutics
Yahoo Finance • last year
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
- Partial spin-off of Bentrio® completed to increase focus on RNA delivery activities - Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Altamira Therap... Full story
Yahoo Finance • last year
Market Today: OpenAI Shakeup and Tech Giants Halt Advertising Amid Controversy
In a surprising turn of events, OpenAI's CEO Sam Altman has been removed from his position by the board of directors, citing a lack of candor in communications. The board has appointed Mira Murati as the interim CEO. This news has had a si... Full story
Yahoo Finance • last year
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
Initiates Strategic Repositioning to Focus on Company’s Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue Hamilton, Bermuda, Nov. 17, 2023 (GLOBE NEWSWIRE)... Full story
Yahoo Finance • last year
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs,... Full story
Yahoo Finance • last year
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Fresh data from randomized controlled NASAR clinical trial further demonstrate efficacy and tolerability of Bentrio® nasal spray in treatment of seasonal allergic rhinitis Study me... Full story
Yahoo Finance • last year
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration with biopharmaceutical company initiated for OligoPhore™ platform Pa... Full story
Yahoo Finance • last year
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, announced that it... Full story
Yahoo Finance • last year
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that... Full story
Yahoo Finance • last year
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira’s OligoPhore delivery platform in the regeneration of damaged heart tissue Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (N... Full story
Yahoo Finance • 2 years ago
Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment
HAMILTON, BERMUDA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Altamira’s ability to target different KRAS mutations with a single polyvalent siRNA sequence illustrates versatility and potential of RNA therapeutics compared with conventional smal... Full story
Yahoo Finance • 2 years ago
Altamira Therapeutics Provides Update on Clinical Trials with Bentrio
HAMILTON, BERMUDA , Jan. 24, 2023 (GLOBE NEWSWIRE) -- Interim analysis of Australian NASAR trial in seasonal allergic rhinitis shows statistically significant improvement with Bentrio® in nasal symptom primary endpoint over saline nasal... Full story
Yahoo Finance • 2 years ago
Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th
Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Company COO Dr. Pañeda will discuss SemaPhoreTM platform’s functionality with mRNA, and:Peptide-based platform for extrahepatic deliveryThe extrahepatic success of, and prospects for,... Full story
Yahoo Finance • 2 years ago
Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results
HAMILTON, BERMUDA, Nov. 30, 2022 (GLOBE NEWSWIRE) -- BentrioTM nasal spray launched in Hong Kong by partner Nuance Pharma to help protect against viruses and allergensCOVAMID trial with Bentrio in acute COVID-19 progressing towards read... Full story
Yahoo Finance • 2 years ago
Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma
Hamilton, Bermuda, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Initiative is Nuance’s first step in penetrating Chinese market with BentrioTMDensely populated Hong Kong (7.3 million) remains negatively impacted by COVID-19Nuance Pharma to file fo... Full story
Yahoo Finance • 2 years ago
Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement
Hamilton, Bermuda, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs today announced that it has regained compliance wit... Full story
Yahoo Finance • 2 years ago
Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamira’s Bentrio under Controlled Grass Pollen Exposure
HAMILTON, BERMUDA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- • Publication in International Archives of Allergy and Immunology shows rapid onset and long duration of Bentrio’s protective effects in allergic rhinitis sufferers • Mean increase o... Full story
Yahoo Finance • 2 years ago
Altamira Therapeutics Announces Reverse Stock Split
HAMILTON, BERMUDA , Oct. 24, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that its Board of Directors has ap... Full story
Yahoo Finance • 2 years ago
Altamira Therapeutics to Host Investor Call on September 14th
HAMILTON, Bermuda, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced it will hold a call to address que... Full story
Yahoo Finance • 2 years ago
Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit
HAMILTON, BERMUDA , Sept. 08, 2022 (GLOBE NEWSWIRE) -- Company’s Chief Scientific Officer Samuel Wickline, MD, to present on the Company’s innovative and patented OligoPhoreTM platform for the treatment of KRAS-driven cancersForum will... Full story
Yahoo Finance • 2 years ago
Altamira Therapeutics Provides Business Update
Company progressing with plans to focus on its RNA businessAdvancing discussions for divestiture or spin-off of legacy assets, including BentrioTM and AM-125 nasal spraysBentrio revenues were $1.3 million in first half of 2022 HAMILTON, B... Full story
